PMID- 33888870
OWN - NLM
STAT- MEDLINE
DCOM- 20220225
LR  - 20230131
IS  - 1476-5500 (Electronic)
IS  - 0929-1903 (Linking)
VI  - 28
IP  - 9
DP  - 2021 Sep
TI  - Delivery technologies to engineer natural killer cells for cancer immunotherapy.
PG  - 947-959
LID - 10.1038/s41417-021-00336-2 [doi]
AB  - In recent years, immune cell-based cancer therapeutics have been utilized broadly 
      in the clinic. Through advances in cellular engineering, chimeric antigen 
      receptor (CAR) T-cell therapies have demonstrated substantial success in treating 
      hematological tumors and have become the most prominent cell-based therapy with 
      three commercialized products in the market. However, T-cell-based 
      immunotherapies have certain limitations, including a restriction to autologous 
      cell sources to avoid severe side-effects caused by human leukocyte antigen (HLA) 
      mismatch. This necessity for personalized treatment inevitably results in 
      tremendous manufacturing and time costs, reducing accessibility for many 
      patients. As an alternative strategy, natural killer (NK) cells have emerged as 
      potential candidates for improved cell-based immunotherapies. NK cells are 
      capable of killing cancer cells directly without requiring HLA matching. 
      Furthermore, NK cell-based therapies can use various allogeneic cell sources, 
      allowing for the possibility of "off-the-shelf" immunotherapies with reduced 
      side-effects and shortened manufacturing times. Here we provide an overview of 
      the use of NK cells in cancer immunotherapy, their current status in clinical 
      trials, as well as the design and implementation of delivery 
      technologies-including viral, non-viral, and nanoparticle-based approaches-for 
      engineering NK cell-based immunotherapies.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.
FAU - El-Mayta, Rakan
AU  - El-Mayta R
AD  - Department of Bioengineering, University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA.
FAU - Zhang, Zijing
AU  - Zhang Z
AD  - Department of Bioengineering, University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA.
FAU - Hamilton, Alex G
AU  - Hamilton AG
AUID- ORCID: 0000-0002-9810-5630
AD  - Department of Bioengineering, University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA.
FAU - Mitchell, Michael J
AU  - Mitchell MJ
AUID- ORCID: 0000-0002-3628-2244
AD  - Department of Bioengineering, University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA. mjmitch@seas.upenn.edu.
AD  - Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, 
      Philadelphia, Pennsylvania, USA. mjmitch@seas.upenn.edu.
AD  - Institute for Immunology, Perelman School of Medicine, University of 
      Pennsylvania, Philadelphia, Pennsylvania, USA. mjmitch@seas.upenn.edu.
AD  - Cardiovascular Institute, Perelman School of Medicine, University of 
      Pennsylvania, Philadelphia, Pennsylvania, USA. mjmitch@seas.upenn.edu.
AD  - Institute for Regenerative Medicine, Perelman School of Medicine, University of 
      Pennsylvania, Philadelphia, Pennsylvania, USA. mjmitch@seas.upenn.edu.
LA  - eng
GR  - R37 CA244911/CA/NCI NIH HHS/United States
GR  - R01 DK123049/DK/NIDDK NIH HHS/United States
GR  - R01 CA241661/CA/NCI NIH HHS/United States
GR  - DGE 1845298/National Science Foundation (NSF)/
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
DEP - 20210422
PL  - England
TA  - Cancer Gene Ther
JT  - Cancer gene therapy
JID - 9432230
SB  - IM
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Killer Cells, Natural/*metabolism
MH  - Neoplasms/*therapy
EDAT- 2021/04/24 06:00
MHDA- 2022/02/26 06:00
CRDT- 2021/04/23 06:17
PHST- 2020/08/24 00:00 [received]
PHST- 2021/03/29 00:00 [accepted]
PHST- 2021/03/09 00:00 [revised]
PHST- 2021/04/24 06:00 [pubmed]
PHST- 2022/02/26 06:00 [medline]
PHST- 2021/04/23 06:17 [entrez]
AID - 10.1038/s41417-021-00336-2 [pii]
AID - 10.1038/s41417-021-00336-2 [doi]
PST - ppublish
SO  - Cancer Gene Ther. 2021 Sep;28(9):947-959. doi: 10.1038/s41417-021-00336-2. Epub 
      2021 Apr 22.